Histamine H1 and serotonin 5-HT2A receptors mediate two different mechanisms involved in sleep regulation: H1 antagonists are sleep inducers, while 5-HT2A antagonists are sleep maintainers. Starting from 9′a, a novel spirotetracyclic compound endowed with good H1/5-HT2A potency but poor selectivity, very high Cli, and a poor P450 profile, a specific optimization strategy was set up. In particular, we investigated the possibility of introducing appropriate amino acid moieties to optimize the developability profile of the series. Following this zwitterionic approach, we were able to identify several advanced leads (51, 65, and 73) with potent dual H1/5-HT2A activity and appropriate developability profiles. These compounds exhibited efficacy as hypnotic agents in a rat telemetric sleep model with minimal effective doses in the range 3−10 mg/kg po.

M., G., Botta, M., S., B., R., C., E., C., C., C., et al. (2010). Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders. JOURNAL OF MEDICINAL CHEMISTRY, 53, 7778-7795 [10.1021/jm100856p].

Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders

BOTTA, MAURIZIO;TOGNINELLI, ANDREA;
2010

Abstract

Histamine H1 and serotonin 5-HT2A receptors mediate two different mechanisms involved in sleep regulation: H1 antagonists are sleep inducers, while 5-HT2A antagonists are sleep maintainers. Starting from 9′a, a novel spirotetracyclic compound endowed with good H1/5-HT2A potency but poor selectivity, very high Cli, and a poor P450 profile, a specific optimization strategy was set up. In particular, we investigated the possibility of introducing appropriate amino acid moieties to optimize the developability profile of the series. Following this zwitterionic approach, we were able to identify several advanced leads (51, 65, and 73) with potent dual H1/5-HT2A activity and appropriate developability profiles. These compounds exhibited efficacy as hypnotic agents in a rat telemetric sleep model with minimal effective doses in the range 3−10 mg/kg po.
File in questo prodotto:
File Dimensione Formato  
jm100856p.pdf

non disponibili

Tipologia: Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 1.35 MB
Formato Adobe PDF
1.35 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11365/9449
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo